In mid-May, pharma giant Pfizer agreed to buy Anacor Pharmaceuticals for a total transaction value, net of cash, of $5.2 billion. Anacor is a biopharmaceutical company concentrated on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform.